BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24152622)

  • 1. Lymph node to primary tumor SUV ratio by 18F-FDG PET/CT and the prediction of axillary lymph node metastases in breast cancer.
    Park J; Byun BH; Noh WC; Lee SS; Kim HA; Kim EK; Choi CW; Lim SM
    Clin Nucl Med; 2014 Apr; 39(4):e249-53. PubMed ID: 24152622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M; Asano T; Kobayashi K; Morimitsu K; Nawa M; Kanematsu M; Morikawa A; Mori R; Yoshida K
    World J Surg Oncol; 2015 Feb; 13():49. PubMed ID: 25885028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting the accuracy of
    Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
    Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
    Choi WH; Yoo IR; O JH; Kim SH; Chung SK
    Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
    Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Value of
    Song BI; Kim HW; Won KS
    Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of the SUV ratio between lymph node and bone marrow in predicting pelvic lymphatic metastasis of patients with locally advanced cervical cancer: an integrated PET/CT study.
    Liu Y; Hua J; Liu L; Zhang W; Xu S; Chen X
    Nucl Med Commun; 2022 Nov; 43(11):1155-1160. PubMed ID: 36003034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
    Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
    Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
    Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A
    Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
    Jung JH; Kim CY; Son SH; Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2015; 10(12):e0144152. PubMed ID: 26636824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
    Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL
    World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
    Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
    Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
    Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
    Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
    He X; Sun L; Huo Y; Shao M; Ma C
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.